• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SpringWorks Therapeutics, Inc. - common stock (NQ:SWTX)

46.99 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about SpringWorks Therapeutics, Inc. - common stock

< Previous 1 2 3 Next >
News headline image
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
October 21, 2025
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and... 
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
August 18, 2025
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors 
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
July 18, 2025
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – 
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPOF, PRA, SWTX on Behalf of Shareholders
June 15, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, SWTX, ICAD, SSBK on Behalf of Shareholders
June 04, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX
June 03, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
May 23, 2025
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders
May 18, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AXL, KRON, PRA, SWTX on Behalf of Shareholders
May 18, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX
April 30, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, COEP, SWTX, CKPT on Behalf of Shareholders
April 30, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
April 28, 2025
From Ademi & Fruchter LLP
Via Business Wire
News headline image
SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders
April 28, 2025
From Halper Sadeh LLC
Via Business Wire
News headline image
Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
April 28, 2025
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
April 27, 2025
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
February 20, 2025
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
February 11, 2025
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
February 11, 2025
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025
January 30, 2025
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 03, 2025
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
November 26, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
November 12, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 12, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
November 11, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
November 11, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
November 07, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
November 05, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
October 22, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
August 28, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap